Safety, tolerability, and pharmacodynamics of ABT-122, a TNF- and IL-17âtargeted dual variable domain immunoglobulin, in patients with RA
Arthritis & Rheumatism Sep 25, 2017
Fleischmann RM, et al. - A two phase 1, placebo-controlled, multiple-dose studies are done to report the pooled safety, tolerability, and exploratory pharmacodynamics of ABT-122 in patients with primarily inactive rheumatoid arthritis (RA). The outcome of this phase 1 study recommends that dual neutralization with ABT-122 has a profile acceptable for further investigation of therapeutic potential in TNF- and IL-17AÂdriven immune-mediated inflammatory diseases.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries